Translational Genomics Research Institute (TGen)
Advancing Arizona’s Bioscience Economy Through Precision Medicine
The Challenge
As a cornerstone of Arizona’s bioscience ecosystem, TGen sought to measure the full scope of its economic and social contributions to the state. With continued growth in precision medicine, research commercialization, and public health response, TGen needed an updated, data-driven analysis to demonstrate the return on investment from state support and showcase its expanding role in driving Arizona’s innovation economy.
How We Helped
Tripp Umbach partnered with TGen to conduct a comprehensive economic and social impact study of the institute’s statewide influence through fiscal year 2020. The analysis measured direct, indirect, and induced impacts for business volume, employment, and government revenue. In addition to evaluating operational spending, Tripp Umbach assessed the broader economic effects of TGen’s research commercialization, including spin-off companies and strategic research partnerships that accelerate technology transfer and public benefit.
Tripp Umbach’s analysis found that TGen generated $657.7 million in total economic impact across operations, commercialization of research, and spin-off activity. Between 2017 and 2020, TGen’s operational impact quadrupled—from $103.3 million to $426.0 million—yielding a return of $85.20 for every state dollar invested. TGen’s operations and related spin-offs supported 2,415 Arizona jobs while driving unprecedented public health advancements, including developing the first FDA-approved COVID-19 diagnostic test and expanding statewide testing capacity through TGen North. Beyond the numbers, TGen continues to fulfill its nonprofit mission by transforming patient outcomes, advancing research, and strengthening Arizona’s biomedical future.